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Development/Plasticity/Repair
Large-Scale Chondroitin Sulfate Proteoglycan Digestion with
Chondroitinase Gene Therapy Leads to Reduced Pathology
andModulates Macrophage Phenotype following Spinal
Cord Contusion Injury
Katalin Bartus,1* Nicholas D. James,1* Athanasios Didangelos,1 Karen D. Bosch,1 Joost Verhaagen,2
Rafael J. Ya´n˜ez-Mun˜oz,3 John H. Rogers,4 Bernard L. Schneider,5 Elizabeth M. Muir,4 and Elizabeth J. Bradbury1
1King’s College London, Regeneration Group, The Wolfson Centre for Age-Related Diseases, London SE1 1UL, United Kingdom, 2Laboratory for
Neuroregeneration, Netherlands Institute for Neuroscience, 1105BA Amsterdam, The Netherlands, 3School of Biological Sciences, Royal Holloway,
University of London, Egham, Surrey TW20 0EX, United Kingdom, 4Department of Physiology Development and Neuroscience, University of Cambridge,
Cambridge CB2 3EG, United Kingdom, and 5Brain Mind Institute, Ecole Polytechnique Fe´de´rale de Lausanne, 1015 Lausanne, Switzerland
Chondroitin sulfate proteoglycans (CSPGs) inhibit repair following spinal cord injury. Here we use mammalian-compatible engineered
chondroitinase ABC (ChABC) delivered via lentiviral vector (LV-ChABC) to explore the consequences of large-scale CSPG digestion for
spinal cord repair.We demonstrate significantly reduced secondary injury pathology in adult rats following spinal contusion injury and
LV-ChABC treatment, with reduced cavitation and enhanced preservation of spinal neurons and axons at 12weeks postinjury, compared
with control (LV-GFP)-treated animals. To understand these neuroprotective effects, we investigated early inflammatory changes fol-
lowing LV-ChABC treatment. Increased expression of the phagocytic macrophage marker CD68 at 3 d postinjury was followed by
increased CD206 expression at 2weeks, indicating that large-scale CSPGdigestion can altermacrophage phenotype to favor alternatively
activated M2 macrophages. Accordingly, ChABC treatment in vitro induced a significant increase in CD206 expression in unpolarized
monocytes stimulated with conditioned medium from spinal-injured tissue explants. LV-ChABC also promoted the remodelling of
specific CSPGs as well as enhanced vascularity, which was closely associated with CD206-positive macrophages. Neuroprotective effects
of LV-ChABC corresponded with improved sensorimotor function, evident as early as 1 week postinjury, a time point when increased
neuronal survival correlated with reduced apoptosis. Improved function was maintained into chronic injury stages, where improved
axonal conduction and increased serotonergic innervation were also observed. Thus, we demonstrate that ChABC gene therapy can
modulate secondary injury processes, with neuroprotective effects that lead to long-term improved functional outcome and reveal novel
mechanistic evidence that modulation of macrophage phenotype may underlie these effects.
Key words: chondroitinase; contusion; gene therapy; neuroprotection; spinal cord injury
Introduction
Amajor obstacle preventing repair following spinal cord injury is
the presence in the extracellular matrix (ECM) of inhibitory
chondroitin sulfate proteoglycans (CSPGs), which becomemore
abundant after injury (Silver andMiller, 2004; Carulli et al., 2005;
Bradbury and McMahon, 2006). Chondroitinase ABC (ChABC)
is a bacterial enzyme that degrades CSPG glycosylated sugar
chains, which are thought to confer much of the inhibitory prop-
erties of CSPGs. In vivo delivery of this enzyme has led to benefi-
cial effects on repair following experimental spinal cord injury in
models involving partial (Bradbury et al., 2002;Houle et al., 2006;
Massey et al., 2006; Cafferty et al., 2008; García-Alías et al., 2009;
Alilain et al., 2011; Jefferson et al., 2011) or complete (Lee et al.,
2013) transection of the spinal cord. However, delivery methods
to date have been suboptimal, largely due to issues of enzyme
instability, which necessitates invasive and repeated administra-
tion to the spinal cord. This is largely thought to be the reason
that ChABChas not proved as effective in treatingmore clinically
relevant contusive-type injuries (involving nonpenetrating blunt
trauma, compression, and bruising). The few studies that have
applied ChABC to injuries that more closely mimic the progres-
sive pathology of a human spinal cord injury have generated
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mixed results, with some beneficial effects on recovery of loco-
motor function reported with ChABC delivered by repeated in-
trathecal infusion (Caggiano et al., 2005; Tauchi et al., 2012) or as
part of a combination therapy (Tom et al., 2009a; Karimi-
Abdolrezaee et al., 2010), while other studies have failed to show
efficacy following single intraspinal ChABC injections (Iseda et
al., 2008; Tom et al., 2009b; Jakeman et al., 2011).
A gene therapy approach, whereby host cells are transduced
with a ChABC viral vector, is emerging as a promising tool for
achieving stable delivery of the ChABC enzyme. A number of
gene delivery methods have been tried, including transcription-
ally targeted glial expression of ChABC in transgenic mice (Caf-
ferty et al., 2007) or Tet-inducible adenoviral vectors (Curinga et
al., 2007) or lentiviral vectors (LVs) (Jin et al., 2011) that encode
engineered chondroitinase AC. However, the degree of CSPG
digestion achieved with these methods has been relatively mod-
est, largely because the eukaryotic N-glycosylation system dis-
rupts folding and secretion of bacterial proteins, resulting in poor
enzyme release by mammalian cells or inactivity of the enzyme.
The recent genetic mutation of bacterial ChABC cDNA by site-
directed mutagenesis of key N-glycosylation sites allows the ex-
pression and efficient secretion of active ChABC enzyme by
mammalian cells (Muir et al., 2010) and LVs incorporating this
mammalian-compatible ChABC gene (LV-ChABCs) have been
produced, with evidence of active ChABC expression and trans-
port following in vivo brain injections and some axonal sprouting
observed in the spinal cord 4 weeks after dorsal column crush
injury and LV-ChABC injection (Zhao et al., 2011).
However, the effects of large-scale CSPG digestion on ECM
remodelling and secondary injury processes in traumatic injuries
more relevant to a human spinal cord injury have not been inves-
tigated. Here we use a potent LV-ChABC and demonstrate that
gene delivery of ChABC leads to significant neuroprotection and
long-term functional repair following spinal contusion injury.
We also reveal a novel interaction between CSPG digestion and
immune modulation that may underlie this repair.
Materials andMethods
Chondroitinase gene
The Proteus vulgaris ChABC gene was modified with mutations targeted
to remove five crypticN-glycosylation sites and addition of amammalian
signal sequence and resynthesized with mammalian preferred codons
(Muir et al., 2010) tomake amammalian-compatible engineeredChABC
gene.
LVs
The modified ChABC cDNA was subcloned into a lentiviral transfer
vector (termed LV-ChABC) with the mouse phosphoglycerate kinase
(PGK) promoter. The production of this vector is described in detail
previously (Zhao et al., 2011). The resulting vector was integrating, self-
inactivating, andpseudotypedwithVSV-G (vesicular stomatitis virusG).
Viral particles were concentrated by ultracentrifugation and titered by a
p24 antigen ELISA assay. The viral titer was 479g/ml P24, correspond-
ing to106 transducing units per microliter. A control lentiviral vector
(termed LV-GFP) was generated from the same transfer vector contain-
ing the cDNA coding for GFP, with a viral titer of 346 g/ml.
Animals
Adult female Sprague Dawley rats (200–220 g; Harlan Laboratories)
were used for all experiments and were housed under a 12 h light/dark
cycle with ad libitum access to food and water. All procedures were per-
formed in accordance with the United Kingdom Animals (Surgical Pro-
cedures) Act 1996. Behavioral testing, electrophysiology, and histological
analyses were all performed by experimenters blinded to treatment.
Spinal cord injury and intraspinal injections
Comparison of ChABC bacterial enzyme with LV-ChABC. Anesthetized
(ketamine, 60 mg/kg, and medetomidine, 0.25 mg/kg) adult female
Sprague Dawley rats received a midline 150 kdyne spinal contusion in-
jury at spinal level T10/11 using an Infinite Horizon’s impactor (Preci-
sion Systems Instrumentation). Immediately after contusion injury, rats
received intraspinal injections (2 0.5l, injected at 1mm rostral and 1
mm caudal to the injury site) of either protease-free ChABC enzyme (10
U/ml, n  6; Seikagaku) or LV-ChABC (n  6). At 3 d and 2 weeks
postinjury, tissue from these animals was taken for biochemical analyses
of chondroitin sulfate glycoaminoglycan (CS-GAG) digestion (n 3 per
group per time point). An additional cohort received contusion injuries
plus intraspinal injections, as above (n 4 per group for LV-ChABC and
ChABC enzyme) or intraspinal injection only (n 4 per group for LV-
ChABC and ChABC enzyme), for histological assessments of CS-GAG
digestion in injured and uninjured animals at 8 weeks postsurgery.
Assessing LV-ChABC in long-term functional and histological studies. A
larger cohort of animals received moderate thoracic contusion injuries
followed by intraspinal injections (as described above) of LV-ChABC or
LV-GFP, while an additional control group received no injection (con-
tusion only). These animals underwent behavioral testing for 10 weeks
postinjury (n 14 all groups), followed by terminal electrophysiological
assessments (n 5 per group) and perfusion for histological assessments
(n 9 per group). Contusion injury surgery, functional assessments, and
anatomical assessments were performed with the experimenter blinded
to treatment group. As all animals achieved comparable baseline scores
on the horizontal ladder task, each animal was randomly assigned to a
treatment group. Randomization to assign animals to treatment groups
was performed by an individual playing no further role in the study, as
were intraspinal injections of each treatment. Immediately following
contusion injury, all animals were taken to the intraspinal injection sur-
gery station, where they received intraspinal (or no) injections; overlying
muscle and skin were then sutured and anesthesia reversed by the indi-
vidual carrying out the intraspinal injections to ensure the individual
carrying out the injury surgery remained blind to treatment group.
Assessing early postinjury changes in inflammation,matrixmodification,
neuroprotection, and vasculature. A further cohort of animals received
moderate thoracic contusion injuries followed by intraspinal injections
(as described above) of LV-ChABC or LV-GFP or were uninjured. At 3 d
and 2weeks postinjury, tissue from these animals was taken for biochem-
ical analyses of inflammatory markers (n 4 per group per time point)
or immunohistochemistry for inflammatory markers (n  3 per group
per time point). A further cohort received moderate thoracic contusion
injuries followed by intraspinal injections (as described above) of LV-
ChABC or LV-GFP. At 1 week (for NeuN and cleaved caspase-3) or 2
weeks [for CD206, rat endothelial cell antigen (RECA), and vascular
endothelial growth factor (VEGF)] postinjury tissue was taken for im-
munohistochemistry (n 3–5 per group per time point). A final cohort
of animals received moderate thoracic contusion injuries (as described
above) or were uninjured (n 6 per group). At 7 d postinjury, tissue was
taken for conditioned medium explant studies.
Electrophysiology: conduction of sensory fibers through the
injury site
Axonal conduction was assessed by antidromic stimulation of sensory
fibers in the dorsal columns in terminal electrophysiology experiments,
as previously described (James et al., 2011). Briefly, the spinal cord was
exposed from T7 to L5 (vertebral levels) in urethane-anesthetized rats
(1.25 g/kg). Antidromic unitary activity was recorded and quantified
from teased dorsal root filaments (left and right L3–S1 roots), while first
stimulating the entire dorsal columns 5mmbelow and then 5mm above
the injury site. Conduction through the injury site was measured by
calculating the number of single units present when stimulating above
the injury site as a percentage of the total number of single units when
stimulating below. Stimulation was continuous during recording ses-
sions and was performed using 0.2-ms-duration square-wave pulses at a
frequency of 1Hz and an incrementally increasing intensity (0–800A).
Stimulationwasmaximal by 400–500A (i.e., no further unitary activity
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could be recruited), but continued to be increased to 800 A to rule out
the possibility of any further, high-threshold fibers.
Behavioral assessments
Hindlimb function and sensorimotor integrationwere assessed using the
horizontal ladder test. This involved the recording of animals making
three runs across a 1 m horizontal ladder with unevenly spaced rungs.
Videos were then analyzed in slow motion to quantify the total number
of hindlimb footslips over the course of the three runs, as previously
described (James et al., 2011). For assessments of pain sensitivity, me-
chanical thresholds were determined bymeasuring latency towithdrawal
using an automated electronic Von Frey, where an increasing force50
g over a 20 s time rampwas applied. Thermal thresholdswere determined
by measuring latency to nocifensive paw withdrawal from a radiant heat
source. Response to a noxious stimulus was also assessed (in the unin-
jured animals only) by injecting 50 l of 5% formalin (37% in sterile
saline) subcutaneously into the left forepaw footpad and quantifying the
time spent licking or biting the affected paw over 45 min.
Tissue processing and immunohistochemistry
Animals were deeply anesthetized with sodium pentobarbital (Euthatal,
80 mg/kg, i.p.) and transcardially perfused with 0.9% saline followed by
4% paraformaldehyde in 0.1 M phosphate buffer. Immediately after per-
fusion, lesion site tissue was dissected (10mmwith the lesion epicenter
located centrally) as well as lumbar (L3–L6) spinal cord. Tissue was post-
fixed for 2 h, cryoprotected in 20% sucrose for 48 h, then embedded and
frozen in Optimum Cutting Temperature Compound before being cut
into serial (20 m) sections, either cut transversely (for all markers ex-
cept NF200) or horizontally [for chondroitin-4-sulfate (C-4-S), NF200,
and RECA-1 only]. Sections were immunostained using the following
primary antibodies: rabbit polyclonal anti-GFAP to label reactive astro-
cytes (1:2000; DakoCytomation), mousemonoclonal anti-NeuN to label
neuronal cell bodies (1:500; Millipore), mouse monoclonal anti-NF200
to label axons (Clone N52, 1:400; Sigma-Aldrich), mouse monoclonal
anti-RECA-1 to label endothelial cells (1:200; Abcam), goat polyclonal
anti-CD206 to identify M2-type macrophages (Kigerl et al., 2009; 1:100;
R&D Systems), mouse anti-CD68 to identify phagocytic inflammatory
cells (1:100; Abcam), rabbit polyclonal anti-5HT to identify serotonergic
projections (1:15,000; ImmunoStar), rabbit polyclonal anti-VEGF, a
marker of angiogenesis (1:2000; Abcam), rabbit polyclonal anti-cleaved
caspase 3, amarker of apoptosis (1:1000; Cell Signaling Technology), and
mouse monoclonal anti-C-4-S to reveal digested sugar stub regions (1:
5000; MP Biomedicals). For anti-C-4-S, anti-VEGF, and anti-cleaved
caspase 3 staining, tyramide signal amplification was used as described
previously (Barritt et al., 2006). Complementary secondary antibodies
were donkey anti-mouse Alexa Fluor 488 (1:1000; Invitrogen), donkey
anti-rabbit Alexa Fluor 546 (1:1000; Invitrogen), donkey anti-goat Alexa
Fluor 488 (1:1000; Invitrogen), and donkey anti-sheep Cy3 (1:100; Jack-
son ImmunoResearch). Images were acquired using Nikon A1R Si Con-
focal Imaging system on a Eclipse Ti-E inverted microscope.
Anatomical quantifications
Cavity size was quantified for n 4 per group using a protocol adapted
from previously published methods, described in detail in James et al.
(2011). Briefly, eriochrome cyanine histochemistry was performed on
serial sections through the injury site. For quantification, images were
taken of sections at 800 m intervals through the injury site and Axiovi-
sion software was used to quantify the total cord area and the cavity area
of each section. Cavity area was then calculated as a percentage of total
cord area for each section. Using Axiovision software, quantification of
NeuN cells was performed on 10 sections per animal, spanning 2 mm
through the lesion epicenter (200 m between sections) and giving a
total value of NeuN cells for all 10 sections combined (n 4 per group
for 12 week time point; n 3 per group for 1 week time point). Quanti-
fication of serotonin (5-HT) and C-4-S intensities was performed in
transverse lumbar spinal cord sections (n 4 per group, n 3 sections
per animal). All sections were photographed under the same exposure.
For 5-HT, the mean pixel value inside a marked area spanning around
the ventral horn was measured for each section. For C-4-S, three areas
weremarked andmeasured in each section, giving amean intensity value
for each section, as previously described (Starkey et al., 2012). This anal-
ysis was performed using ImageJ (version 1.38; National Institute of
Health). Quantification of cleaved caspase-3 at 1 week postinjury (n 5
per group) was performed by unbiased particle counts following back-
ground subtraction (ImageJ software). Images were acquired sequen-
tially using the same exposure parameters. All anatomical quantification
was performed by an experimenter blinded to the treatment group.
Electrophoresis and immunoblotting
For immunoblotting, rats were killed with a lethal injection of sodium
pentobarbital and perfused with 150 ml of PBS supplemented with 12.5
mM EDTA to inhibit platelet aggregation and metalloproteinase activity.
Spinal cord segments of 5–6mmwere carefully dissected at the T10 level
to include the entire injury epicenter. Additional tissue segments from
caudal (lumbar) and rostral (cervical spinal cord and cortex) regions
were also dissected to assess the rostrocaudal extent of digested CS-
GAGs. Tissue was weighed and placed on ice-cold PBS, and supple-
mented with 12.5 mM EDTA and a broad proteinase inhibitor mixture
(P8340, Sigma-Aldrich). Before protein extraction, spinal cord speci-
mens were washed three times with the PBS solution to minimize con-
tamination with plasma proteins. Tissue proteins were then extracted as
previously described (Didangelos et al., 2011). Cellular and ECMprotein
extracts were denatured and reduced in 4 sample buffer containing 500
mM Tris, pH 6.8, 40% glycerol, 0.2% SDS, 2% -mercaptoethanol, and
0.02% bromophenol blue, and boiled at 98°C for 10 min. Twenty-five
micrograms of protein per sample were loaded and separated on 15-well,
Bis-Tris 10% polyacrylamide gels (NuPAGE, Invitrogen). Proteins were
then transferred on nitrocellulose membranes. Membranes were stained
with Ponceau red stain to visualize successful transfer and to confirm
equal protein loading, blocked in 5% fat-free milk powder in PBS, and
probed for 16 h at 4°C with different primary antibodies: mouse anti-
CD68, mouse anti-actin, mouse anti-brevican, mouse anti-neurocan
(Abcam), goat anti-CD206 (R&D Systems), rabbit anti-versican, rabbit
anti-aggrecan, (Santa Cruz Biotechnology), rabbit anti-Iba1 (Wako),
and mouse anti-C-4-S GAG stubs (MP Biomedicals). Antibodies were
used at 1:500 dilution in 5% BSA PBS. Following three washes in PBS
Tween 20, membranes were incubated with the appropriate horseradish
peroxidase-conjugated secondary antibodies (Dako Cytomation) in 5%
milk powder at 1:2000 dilution for 1 h at room temperature. Finally, blots
were treated with enhanced chemiluminescence (ECL) reagents (GE
Healthcare) and films were developed in a Kodak processor. Densitom-
etry of developed blots was performed using ImageJ and values were
normalized to -actin.
Cell culture and conditioned medium studies
THP-1 monocytic model cells were used for in vitro culture experiments
at passage 3–4. Cells were expanded to 1 million cells per milliliter and
kept in DMEM supplemented with 10% fetal calf serum and penicillin/
streptomycin. Before stimulation, cells were serum starved in plain
DMEM for 3–4 h. Theywere then incubated for 24 h in either spinal cord
conditioned medium or left untreated in serum-free medium as indi-
cated. Conditionedmediumwas generated as follows: contusion-injured
(7 d, n 6) or uninjured control animals (n 6) were perfused in sterile
PBS containing 12.5 mM EDTA tominimize plasma contamination. T10
spinal cord segments (5–6 mm, containing the entire injury epicenter or
uninjured cord) were carefully dissected using sterile instruments and
washed three times in PBS with penicillin/streptomycin antibiotics. Spi-
nal cord explants were then weighed and placed in three weight volumes
of either serum-free DMEM (n  3) or in serum-free DMEM supple-
mented with 0.05 U ChABC (n  3; protease-free ChABC, Sigma-Al-
drich; 10 U dissolved in DMEM at 100 U/ml), to deglycosylate cord
CSPGs, and cultured for 24 h at 37°C. The conditioned medium from
untreated or ChABC-treated explants was then collected, diluted 1:1 in
serum-free DMEM, and applied on serum-starved THP-1 cells for 24 h.
CD206 mRNA expression was measured using the TaqMan real-time
PCR system (Applied Biosystems). RNA was isolated from THP-1 cells
and treated with the conditioned medium described above, using a total
RNA extraction kit (Omega Bio-Tek). One thousand nanograms of RNA
was converted into cDNA using the high-capacity RNA-to-cDNA kit
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(Applied Biosystems). Ten nanograms of RNA/reaction was quantified
using a human cd206 TaqMan prevalidated primer/probe mix
(Hs00267207_m1), at a concentration of 900 nM for the primer and 200
nM for the probe. Real-time PCR was performed using an automated
Roche thermocycler. Data analysis was performed using the Ct
method, where the transcript levels of CD206 in conditioned-medium-
treated cells were comparedwithCD206 expression in untreated, control
cells. Eukaryotic 18s ribosomal RNA (Hs99999901_s1) served as the
housekeeping gene to normalize levels of CD206 expression. All samples
were measured in duplicate. For CD206 protein levels, THP-1 cells were
treated with the same conditioned medium described above. Following
24 h stimulation, the cells were lysed in 0.2% SDS and 25 g of protein
per sample were immunoblotted with antibodies against CD206, as de-
scribed above. For CD206 immunostaining, THP-1 cells were fixed in
2% paraformaldehyde for 15 min, blocked in 5% donkey serum, and
immunostained with goat anti-CD206 (1:100; R&D Systems) antibodies
followed by Alexa Fluor 488 donkey anti-goat (1:500) secondary anti-
bodies. Nuclei were counterstained with DAPI.
Statistical analyses
All numerical values are reported as mean 
SEMand all statistical analyses were performed
using GraphPad Prism v5 software. Behavioral
data were analyzed by two-way repeated-
measures (RM) ANOVA, while histological,
immunoblot, and electrophysiological data
were analyzed by one-way ANOVA in in-
stances of multiple comparisons and by un-
paired Student’s t test in instances of single
comparisons. Post hoc comparisons were per-
formed where appropriate; all statistical tests
are stated in the text.
Results
LV delivery of mammalian-compatible
engineered ChABC under a PGK
promoter leads to large-scale CSPG
digestion in the adult mammalian
spinal cord
To assess efficacy of ChABC gene deliv-
ery, we first assessed the extent of CSPG
digestion that could be achieved with an
LV-expressing mammalian-compatible
ChABC driven by a PGK promotor
(LV-ChABC), compared with conven-
tional ChABCbacterial enzyme, following
intraspinal injection into uninjured or
contused adult rat spinal cords (Fig. 1).
Extent and rostrocaudal spread of CSPG
digestion was quantified with Western
blot analyses of tissue homogenates from
the injury epicenter and from caudal
(lumbar cord) and rostral (cervical cord
and cortex) regions at two postinjury time
points (3 d and 2 weeks) following contu-
sion and intraspinal injection (Fig. 1A,B).
This revealed abundant C-4-S stubs (indi-
cating CS-GAG digestion) at the injury
epicenter at 3 d postinjury following LV-
ChABC injection, which increased further
by 2 weeks postinjury. By comparison,
much lower levels of C-4-S were achieved
with injections of ChABC bacterial en-
zyme (C-4-S levels were significantly
higher at both time points following LV-
ChABC compared with bacterial ChABC;
p 0.05 and p 0.001, respectively, one-
way ANOVA, Bonferroni’s post hoc; Fig. 1A,B). In addition to
causing more potent CSPG digestion at the T10 injury epicenter,
LV-ChABC also led to more widespread CSPG digestion, with
abundant C-4-S in the lumbar spinal cord and, to a lesser extent,
the cervical spinal cord, but negligible C-4-S expression in brain
cortex. C-4-S levels were negligible in all rostrocaudal regions
with ChABC bacterial enzyme injections, indicating that treat-
ment was restricted to the epicenter only (Fig. 1A,B). Thus, gene
delivery of mammalian-compatible ChABC leads to more in-
tense and widespread CSPG digestion in the adult mammalian
spinal cord than with conventional ChABC bacterial enzyme.
CSPG digestion was also examined in histological sections at a
later (8 week) time point following intraspinal injection of LV-
ChABC or ChABC bacterial enzyme in uninjured and contused
animals (Fig. 1C–F). Eight weeks after intraspinal injection, there
was still evidence of digested CSPGs in the spinal cord. However,
Figure 1. LV delivery of mammalian-compatible engineered ChABC under a PGK promoter leads to large-scale CSPG digestion
in the adult mammalian spinal cord; comparison of bacterial ChABC enzyme versus LV-ChABC. A, Immunoblotting for C-4-S stubs
was used to compare GAG digestion in the injury epicenter (T10) of conventional ChABC enzyme-treated and LV-ChABC-treated
cords at 3 d and 2 weeks following spinal contusion. Lumbar (L2) and cervical (C4) segments as well as brain cortex were also
blotted to visualize the spread of GAG digestion at 2 weeks postinjury. B, For ChABC and LV-ChABC injury epicenter comparisons,
results are mean density values SEM; n 3 cords; *p 0.05; ***p 0.001, one-way ANOVA and Bonferroni’s multiple-
comparison test. For the lumbar, cervical, and cortex, each lane is a pool of extracts derived from three animals. C–F, Immunohis-
tochemistry in sagittal sections through the uninjured (C, D) or the injured (E, F ) thoracic spinal cord showing the C-4-S (green)
digestion pattern at 8 weeks postinjection with or without contusion injury. In uninjured spinal cords, weak C-4-S immunoreac-
tivity restricted to the injection zonewas apparent 8 weeks following injection of bacterial ChABC (C), compared with intense and
widespread C-4-S immunoreactivity with LV-ChABC injection (D). Abundant CSPG digestion was also observed at the injury
epicenter 8weeks following contusion and LV-ChABC injection, and the lesion site appeared to be associatedwith numerous tissue
bridges (F ). By comparison, the injury epicenter following intraspinal injection of conventional ChABC enzyme contained lower
levels of digested CSPGs at 8 weeks postinjury and the epicenter had developed into a large cavity (E). These data suggest that
large-scale CSPG digestion achieved by LV-ChABC may have a neuroprotective effect. Scale bar: (in F ) C–F, 1 mm.
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Figure 2. Gene delivery of ChABC leads to improved injury pathology and neuroprotection following spinal contusion. A–C, Eriochrome cyanine histochemistry in transverse spinal cord sections
12weeks following spinal contusion shows amarked reduction in cavity formation at the lesion epicenter following LV-ChABC treatment (C), comparedwith contusion only (A) or LV-GFP treatment
(B). D, Quantification of cavity area reveals a significant reduction in cavity size at the epicenter following LV-ChABC treatment as well as in the rostrocaudal spread of the cavity (asterisks indicate
a significant difference comparedwith both contusion only and contusion plus LV-GFP; p 0.05, 2-way repeated-measures ANOVA, Bonferroni’s post hoc). E, F, Merged images of GFAP (astrocytes,
red) and NeuN (neurons, green) immunoreactivity throughout the rostrocaudal axis. Dramatic changes in reactive gliosis and neuronal cell survival after contusion injury and LV-ChABC treatment
(F ) compared with contusion-only controls (E) were observed. I, Quantification of averaged NeuN-positive cells counted over a series of sections from 1mm rostral to 1mm caudal to the epicenter
revealed a significant preservation of spinal neurons following LV-ChABC treatment, comparedwith contusion only and LV-GFP treatment; *p 0.05, one-way ANOVA, Tukey’s post hoc.G,H, The
much reduced lesion epicenter in LV-ChABC-treated spinal cord contains numerous blood vessels, indicated by RECA-1 immunoreactivity (green). J–L, While large cystic cavities are apparent in
chronically injured spinal cords (12 weeks postinjury) that are untreated or received LV-GFP treatment, numerous NF 200-positive axons (green) are apparent coursing through the lesion
epicenter in LV-ChABC-treated spinal cords. A’–D’, High-magnification images of the areas indicated in E and F. Scale bars: (in C) A–C, 500m; (in E) E, F, 500m; H, 500m; (in L)
J–L, 500m; (in D’) A’–D’, 100m.
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in naive animals injected with ChABC bacterial enzyme, C-4-S
immunoreactivity was low and was restricted to a central zone
around the injection site (Fig. 1C), whereas intense and more
widely distributed C-4-S stub immunoreactivity was apparent in
the spinal cords of animals injectedwith LV-ChABC8weeks after
injection, indicating sustained and widespread delivery of active
enzyme with LV-ChABC (Fig. 1D). Similar intense C-4-S immu-
noreactivity was apparent at 8 weeks in animals that received
intraspinal injection of LV-ChABC immediately following spinal
contusion (Fig. 1F) and again C-4-S expression was much lower
and less widespread in contused animals injected with ChABC
bacterial enzyme (Fig. 1E). Interestingly, abundant CSPG diges-
tion in the injury epicenter at early postinjury time points (Fig.
1A,B) appeared to be associated with evidence of tissue preser-
vation at 8 weeks postinjury in this initial histological analysis,
with smaller cavities and many tissue bridges apparent in LV-
ChABC-injected animals (Fig. 1F). Conversely, following bacte-
rial ChABC injection, where levels of digested CSPGs were much
lower within the epicenter at early postinjury time points (Fig.
1A,B), large cavities had formed at the injury epicenter 8 weeks
after contusion injury (Fig. 1E). These data provide initial evi-
dence that large-scale CSPG digestion achieved by LV-ChABC
may lead to reduced secondary injury pathology following spinal
contusion injury.
Gene delivery of ChABC leads to reduced secondary injury
pathology following spinal cord injury
Potential neuroprotective effects of large-scale CSPG digestion
were investigated in more detail by examining whether LV-
ChABC could reduce the progressive pathology that occurs fol-
lowing spinal contusion, and that is largely responsible for the
permanent loss of function (Schwab and Bartholdi, 1996).
Animals received thoracic contusion injuries and intraspinal
injections of either LV-ChABC or a control GFP-expressing LV
(LV-GFP) or no injection (contusion only). Stereological quan-
tification of eriochrome cyanine staining in serial sections from
3.6 mm rostral to 3.6 mm caudal to the injury epicenter at a
chronic (12 weeks) postinjury time point revealed a remarkable
reduction in cavity size apparent at the lesion epicenter following
LV-ChABC treatment (1 l injected at the time of injury), com-
pared with untreated or LV-GFP-treated animals (Fig. 2A–C)
and significantly reduced spread of cavitation (p 0.01 two-way
repeated-measures ANOVA; Fig. 2D). Since contusion injury
leads to mass destruction of spinal gray matter, extensive neuro-
nal cell loss typically occurs along the rostrocaudal extent of the
injury, with the lesion epicenter characteristically devoid of spinal
neurons.While we observed this pattern in untreated (Fig. 2E, A’
and B’) and LV-GFP-treated animals at 12 weeks following spinal
contusion, many neuronal cell bodies were apparent at the injury
epicenter and in rostrocaudal spinal segments following LV-
ChABC treatment, corresponding to areas of reduced pathology
and cavitation (Fig. 2F, C’ and D’), revealed by GFAP and NeuN
immunohistochemistry in serial sections through the injury.
Quantification of the number of surviving spinal neurons
(summed total cell counts in 10 serial sections from 1 mm
rostral to 1 mm caudal to the epicenter) revealed a significant
50% increase in the number of spinal neurons surviving the
trauma following LV-ChABC treatment, compared with contu-
sion only and contusion plus LV-GFP (3084 273, 1750 359,
and 2014 353 NeuN-positive cells, respectively; p 0.05; one-
way ANOVA, Tukey’s post hoc; Fig. 2I). Additionally, we noted
altered reactive gliosis after LV-ChABC treatment, where GFAP-
positive astrocytic processes appeared more diffuse and elon-
gated, compared with the thick border of reactive astrocytes
typically observed around the cavity borders following contusion
only or treatment with control LV-GFP (Fig. 2, compare GFAP
immunoreactivity in E, F epicenter). To ascertain whether tissue
at the epicenter was viable and contained axonal projections, we
examined vasculature with RECA-1 (an endothelial cell marker)
and spinal axons with NF200 (an axonal marker) immunohisto-
Figure 3. Gene delivery of ChABC leads to alterations in macrophage markers. A, B, Immu-
noblotting for CD68, CD206, and IBA1 in the injury epicenter of either LV-GFP-treated or LV-
ChABC-treated cords 3 d and 2 weeks following spinal contusion (samples from individual
animals are shown in each lane). Uninjured, control (CON) T10 spinal cord tissue was used for
comparison. Values were normalized to-actin. Results aremean density values SEM; n
3–4 cords; *p 0.05; one-way ANOVA and Bonferroni’s multiple-comparison test. C–F, Dou-
ble labeling of either CD68 or CD206 (green) with IBA1 (red) shows an early increase in CD68
immunostaining in the injury epicenter 3 d after contusion and LV-ChABC injection (D) followed
by increased CD206 immunostaining at 2 weeks (F ), compared with LV-GFP (C, E). Scale bar:
(in F ) C–F, 500m.
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chemistry in longitudinal sections
through the injury site. Confocal images
of contused spinal cords at the lesion epi-
center following no treatment or after LV-
GFP or LV-ChABC delivery revealed that
the much reduced lesion epicenter was
well vascularized following LV-ChABC
treatment, with numerous blood vessels
apparent through the lesion core (Fig.
2G,H). Furthermore, NF200-positive ax-
ons were abundant in the lesion epicenter
following LV-ChABC treatment (Fig. 2L),
in stark contrast to the axon-free large
cavities in untreated or LV-GFP-treated
contused spinal cords (Fig. 2 J,K). Thus, a
single administration of LV-ChABC at the
time of injury preventedmuch of the hall-
mark secondary pathology that is typically
observed in chronic spinal cord-injured
tissue.
Gene delivery of ChABC induces
macrophage, vascular, and ECM
changes following spinal cord injury
Local and infiltrating macrophages are
key effectors of tissue remodelling and re-
pair following injury. Therefore, since our
data indicated that gene delivery of
ChABC led to a significant improvement
in tissue preservation (Fig. 2), we assessed
whether LV-ChABC treatment could alter
macrophage responses in vivo following
spinal contusion. Immunoblotting was
used to characterize macrophage pheno-
typic properties in the lesion epicenter at 3 d
and 2 weeks following spinal contusion
and intraspinal injection of LV-ChABCor
LV-GFP, in comparison with uninjured
tissue (Fig. 3A,B). The phagolysosomal
marker CD68 was significantly increased
in LV-ChABC-treated cords 3 d postin-
jury compared with LV-GFP-treated ani-
mals, whereas at 2 weeks post injury,
CD68 was significantly reduced in LV-
ChABC-treated cords, which instead showed a significant up-
regulation of CD206, the main marker of alternative (M2)
macrophage activation (all comparisons p  0.05 one-way
ANOVA, Bonferroni’s post hoc; Fig. 3A,B). IBA1 levels were
comparable in LV-GFP and LV-ChABC treatments (both being
increased comparedwith uninjured controls; Fig. 3A,B), indicat-
ing that overall microglia/macrophage numbers were similar and
that LV-ChABC specifically affects macrophage phenotype.
Immunohistochemical analyses on a further set of animals
confirmed the early (3 d) increase in CD68-positive cells in LV-
ChABC-injected cords (Fig. 3C,D) followed by an increase in
CD206-positive cells at 2weeks postinjury (Fig. 3E,F), compared
with LV-GFP-injected cords, with overall comparable macro-
phage/microglia staining (IBA1 immunostaining) within the le-
sion epicenter with both treatments (Fig. 3C–F). CD206 and
IBA1double immunofluorescence revealed areas of clear colocal-
ization as well as areas of confined single staining for CD206 in
the lesion epicenter (Fig. 3E,F). This suggests either differential
activation of microglia/macrophages in the epicenter or an infil-
trating origin of the CD206-positive cells.
In support of the in vivo findings, conditioned medium sam-
pled from injured T10 spinal cord explants cultured ex vivo in-
duced the expression of CD206 protein on resting THP-1 cells (a
simple model of unpolarized and undifferentiated monocytes).
CD206 expression was further increased with conditioned me-
dium from ChABC-treated explants (Fig. 4A,B; p  0.05 one-
way ANOVA, Bonferroni’s post hoc). In contrast, conditioned
medium sampled from uninjured T10 explants did not induce
CD206 expression with or without ChABC treatment (Fig.
4A,B). The effect of ChABC-treated explant conditioned me-
dium on the upregulation of CD206 was confirmed at the
mRNA level (Fig. 4C; p 0.05 one-way ANOVA, Bonferroni’s
post hoc). Finally, immunofluorescence highlighted the low
baseline expression of CD206 on the unpolarized monocytic
cells and confirmed its upregulation following treatment with
injured cord conditioned medium, which was further en-
hanced in cells stimulated with ChABC-treated injured cord
Figure 4. Conditioned medium from cultured spinal cord-injured explants induces CD206 expression on unpolarized THP-1
cells. A–D, Unpolarized THP-1 human monocytic cells were treated with conditioned medium (CM) derived from either control
uninjured (CONCM) or 7 d injured (injured CM) T10 spinal cord segments, cultured for 24 h at 37°C, in plainDMEMor supplemented
with 0.05UChABCenzyme, to deglycosylate cord CSPGs.A, Immunoblotting revealed that injured CM induced CD206upregulation
on THP-1 cells and this effect was enhanced by ChABC activity. B, CD206 immunoblots were quantified by densitometry. Values
were normalized to -actin. Results are mean density values SEM; n 3 independent experiments; *p 0.05; one-way
ANOVA and Bonferroni’s multiple-comparison test. C, The upregulation of CD206 was also confirmed at the mRNA level using
quantitative PCR. Relative expression was quantified using theCt method. CD206 PCR signal was normalized to 18s (house-
keeping gene). n 3 independent experiments; *p 0.05. One-way ANOVA and Bonferroni’s multiple-comparison test. D,
CD206 immunostaining (green) in cultured THP-1 cells treated with injured CM. Nuclei were counterstained with DAPI (blue).
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conditioned medium (Fig. 4D). These data indicate that the
expression of CD206 is mediated by soluble factor(s) present
in the injury site and underlines the role of the proteoglycan
matrix in their regulation.
To look at potential vascular changes following LV-ChABC
treatment, double immunostaining in 2-week-postinjury tissue
revealed that the numerous CD206-positive cells in the lesion
epicenter of LV-ChABC-treated cords were closely associated
with VEGF, a key angiogenic cytokine (Fig. 5B,b’). This associa-
tion was less pronounced in LV-GFP-treated animals, which in-
stead showed few CD206-positive macrophages and lower levels
of VEGF in the lesion epicenter, but strong VEGF staining within
the thick astroglial lesion border (Fig. 5A,a’). In LV-ChABC-
treated animals, CD206-positive cells were also closely associated
with numerous RECA-1-positive blood vessels in the lesion epi-
center (Fig. 5C,c’), consistentwith thewell established angiogenic
properties of M2 macrophages. However, at sites more proximal
to the injury epicenter, CD206-positive cells were also apparent
in themeninges and clearlywithinRECA-1-positive blood vessels
(Fig. 5D,d’), indicating a potential infiltrating origin of the cells.
Since changes in the inflammatory response could have a neu-
roprotective function, we also performed immunostaining for
neuronal cell bodies at an early (7 d) postinjury time point (Fig.
6A,B). LV-ChABC-treated cords showed a significant increase in
NeuN-positive cells through the lesion site (p  0.05; unpaired
two-tailed Student’s t test; Fig. 6E). The increased neuronal sur-
vival in LV-ChABC-treated animals was accompanied by a sig-
nificant reduction in the expression of cleaved (activated)
caspase-3, a critical mediator of apoptosis, in the injury epicenter
(p  0.05; unpaired two-tailed Student’s t test; Fig. 6C,D,F).
Accordingly, there was a clear negative correlation (r  	0.82,
Spearman correlation coefficient), between NeuN counts and
cleaved caspase-3 in the injury epicenter of LV-GFP-treated and
LV-ChABC-treated cords.
We also examined changes in ECM proteins following large-
scale CSPG digestion. CSPG levels in the injury epicenter were
examined by immunoblotting at 3 d and 2weeks following spinal
contusion and intraspinal injection of LV-ChABC or LV-GFP
compared with tissue from uninjured animals (Fig. 7A,B). LV-
ChABC treatment had a differential effect on the protein levels of
aggrecan and versican at 2 weeks postinjury, with aggrecan sig-
nificantly increased and versican significantly decreased in the
epicenter of LV-ChABC-injected cords, comparedwith LV-GFP-
injected cords (Fig. 7A,B). Brevicanwas significantly increased at
3 d only, while neurocan was unaffected by the treatment (Fig.
7A,B). Versican has been previously shown to be upregulated in
humanM1macrophages polarized in vitro (Martinez et al., 2006)
and has been implicated in classical inflammatory activation via
TLR2 (Kim et al., 2009). Therefore the decrease in versican, cou-
pled with the increase in CD206 observed in LV-ChABC-treated
cords, supports the hypothesis that ChABC activity (confirmed
by C-4-S immunoblotting; Fig. 7A) promotes alternative macro-
phage activation after injury.
Gene delivery of ChABC leads to improved sensorimotor
function and spinal conduction following spinal cord injury
Wealso examinedwhether LV-ChABC could improve long-term
functional outcome following spinal contusion. Force readouts
from individual animals confirmed consistent reproducible inju-
ries across all experimental groups (Fig. 8A). Functional effects
were assessed using the horizontal ladder test, a skilledmotor task
requiring fine sensorimotor integration, and this revealed clear
differences between the treatment groups (Fig. 8B). While both
control groups (contusion only and contusion plus LV-GFP
treatment) were severely and significantly impaired throughout
the testing period, making many footslip errors as they traversed
the ladder, LV-ChABC-treated animals showed a markedly im-
proved recovery of function. Improved function was observed as
early as 1 week postinjury (33.1  3.5 footslip errors for LV-
ChABC compared with 48.8  3.5 and 47.1  3.9 for LV-GFP
and contusion only, respectively; Fig. 8B), in line with the
histological observations of neuroprotection 1 week following
LV-ChABC treatment. Importantly, improved function in LV-
ChABC-treated animalswas sustained into chronic stages postin-
jury (footslip errors at 10weeks postinjury: 14.6 1.6, 28.3 2.8,
29.7  3 for LV-ChABC, LV-GFP, and contusion only, respec-
tively), with LV-ChABC-treated rats showing significantly fewer
Figure 5. CD206-positive macrophages are closely associated with improved vascularity. A,
B, At 2 weeks postinjury, the numerous CD206-positive cells (green) in the injury epicenter of
LV-ChABC-treated cords were closely associated with VEGF (red), compared with LV-GFP-
treated cords where few CD206-positive cells were observed in the epicenter and VEGF was
concentrated mainly around the lesion border (boxed areas shown at high magnification in a’
and b’). LV-ChABC-treated cords were also double stained for CD206 (green) and the endothe-
lial cell marker RECA-1 (red), revealing CD206-positive areas that were highly vascularized in
the injury epicenter (C and c’ highmagnification) and perilesional andmeningeal blood vessels
which contained CD206-positive cells at sites more distal to the injury (D and d’ high magnifi-
cation). Scale bars: (in A) A, B, 200m; (in C) C, D, 200m.
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footslip errors compared with both con-
trol groups throughout the testing period
(p  0.01 at all postinjury time points;
two-way repeated-measures ANOVA,
Bonferroni’s post hoc; Fig. 8B).
We then used electrophysiology to as-
sess whether LV-ChABC could lead to im-
proved conduction of spinal axons
following contusion injury (Fig. 8C,D).
Axonal conduction in long-distance sen-
sory projections in the spinal cord is se-
verely and chronically impaired in this
injury model, with only a small percent-
age of axons capable of conducting
through the injury site (James et al., 2011).
Single-unit recordings of dorsal column
axons activated antidromically above and
below the T10 contusion site at 10 weeks
postinjury revealed a significant effect of
LV-ChABC treatment on restoring sen-
sory fiber conduction,with the percentage
of fibers capable of conducting across the
contusion injury significantly increased in
LV-ChABC animals compared with ani-
mals with contusion only or contusion
plus LV-GFP (23.1  2.9%, compared
with 10.4 0.6% and 11.3 2%, respec-
tively; p 0.01 one-wayANOVA,Tukey’s
post hoc; Fig. 8C). Thus, a single adminis-
tration of LV-ChABC at the time of injury
led to improved conduction of spinal ax-
ons at a chronic postinjury time point fol-
lowing spinal contusion.
Gene delivery of ChABC leads to
increased density of descending
serotonergic projections following
spinal cord injury
Since awell known consequence of digest-
ing CSPGs with ChABC is to enhance ax-
onal sprouting, we determined whether
large-scale CSPG digestion following LV-
ChABC treatmentwould lead to increased
serotonergic input onto targets caudal to
the injury. Serotonin (5-HT) immunohis-
tochemistry was examined in the ventral
horn of the lumbar spinal cord 10 weeks
following contusion and intraspinal injec-
tion. Dense serotonergic innervation was
apparent in the ventral hornof LV-ChABC-
treated animals, in contrast to low 5-HT-
immunoreactivity in the ventral horn of
animals with contusion only or contusion
plus LV-GFP (Fig. 9A–C), with a significant
increase in serotonergic fiber density (mean 5-HT pixel intensity
values of 122.2 13.1 compared with 67.03  12.7 and 74.13 
9.1, respectively; p  0.05 one-way ANOVA; Fig. 9D). Corre-
sponding to increased serotonergic input, we observed intense
C-4-S immunoreactivity in the lumbar spinal cordofLV-ChABC-
treated animals, which was absent in contusion-only or GFP-
treated animals (C-4-S mean pixel intensity, 41.35  8.35,
compared with 4.28  0.53 and 4.86  1.36, respectively; p 
0.001 one-way ANOVA; Fig. 9E–G). These findings suggest
that widespread CSPG digestion achieved with LV-ChABC can
promote changes in serotonergic fiber density, below the level of
a spinal cord injury.
The potential for large-scale CSPG digestion to promote
sprouting and novel connectivity could potentially lead to det-
rimental consequences, such as enhanced pain. We therefore
performed behavioral assessments to determine withdrawal
thresholds to thermal and mechanical stimulation of the paw
and tomonitor pain behavior following formalin injection (Fig. 10).
Figure 6. Gene delivery of ChABC leads to reduced neuronal death associated with lower levels of apoptosis at 1 week postin-
jury. A, B, Serial images of NeuN (neurons, green) immunoreactivity throughout the rostrocaudal axis showing greater survival of
spinal neurons at 1 week postinjury following LV-ChABC treatment, compared with LV-GFP treatment. C, D, Cleaved caspase-3
immunoreactivity in the lesion epicenter reveals a clear reduction in the apoptoticmarker at 1weekpostinjury following LV-ChABC
treatment, compared with LV-GFP treatment. E, Quantification of total NeuN-positive cells counted in serial sections from 1 mm
rostral to 1 mm caudal to the epicenter revealed a significant preservation of spinal neurons following LV-ChABC treatment,
comparedwith contusion only and LV-GFP treatment; *p 0.05, unpaired two-tailed Student’s t test. F, Quantification of cleaved
caspase-3 activity in the lesion epicenter revealed reduced levels of apoptosis following LV-ChABC treatment, compared with
LV-GFP controls; *p 0.05, unpaired two-tailed Student’s t test. Scale bar: (in C) A–D, 500m.
Figure 7. Gene delivery of ChABC promotes remodelling of specific CSPGs following spinal contusion. A, Immunoblotting for
aggrecan, versican, brevican, and neurocan in the injury epicenter of either LV-GFP-treated or LV-ChABC-treated cords at 3 d and
2weeks following spinal contusion (samples from individual animals are shown in each lane). Uninjured, control (CON) T10 spinal
cord tissue was used for comparison. A switch in the expression of specific CSPGs was observed, with increased aggrecan and
decreased versican apparent at 2 weeks postinjury following LV-ChABC treatment, compared with LV-GFP treatment. B, Protein
levels were estimated by densitometry. Results are mean density values SEM; n 4 cords; *p 0.05; one-way ANOVA and
Bonferroni’smultiple-comparison test. Immunoblottingagainst theC-4-SGAGstubsdemonstrates LV-ChABCenzymatic activity in
the injury epicenter.
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There were no significant differences observed in paw with-
drawal thresholds or in response duration to the painful stim-
ulus between LV-ChABC-treated and control-treated groups;
this was apparent in both uninjured (Fig. 10A–D) and injured
(Fig. 10E,F ) animals. These data provide evidence that long-
term CSPG digestion does not lead to enhanced pain
sensitivity.
Discussion
Here we demonstrate that gene delivery of mammalian-compatible
ChABC leads to large-scale digestion of CSPGs in the spinal cord,
which results in neuroprotection and long-term improved func-
tional outcome following spinal contusion injury. Moreover, we
reveal a direct association between CSPG digestion and modula-
tion of macrophage phenotype to favor alternatively activated
M2macrophages, whose ability to promote resolution of inflam-
mation, positive tissue remodelling, and angiogenesis provides a
mechanism underlying the tissue sparing and neuroprotection
observed following ChABC gene delivery.
Large-scale CSPG digestion with ChABC gene delivery
Large-scale expression of ChABC has not previously been
shown. Due to issues of enzyme stability, ChABC has typically
been administered via repeated bolus injections into indwell-
ing catheters placed intrathecally at the lesion site (Bradbury
et al., 2002; Caggiano et al., 2005; Iaci et al., 2007; García-Alías
et al., 2009) or in the intracerebroventricular system (Carter et
al., 2008, 2011; Starkey et al., 2012). Thermostablizing the en-
zyme can prolong the activity of ChABC and effectively reduce
CSPG levels at lesion boundaries for 6 weeks following one ad-
ministration (Lee et al., 2010), although delivery remains re-
stricted to the injection site. Here we show efficient delivery of
active enzyme for at least 3months after LV-ChABC delivery and
that ChABC delivery is widespread, with digested CSPGs appar-
ent over several spinal segments spanning the injury epicenter,
and as far caudal as the lumbosacral spinal cord. These findings
indicate stable and long-term expression of the transgene and
widespread secretion of active ChABC enzyme following in-
traspinal injection of LV-ChABC.
While there is much evidence that intraparenchymal injec-
tions of regular ChABC bacterial enzyme can lead to functional
improvements in partial injury models (Pizzorusso et al., 2002;
Massey et al., 2006; Cafferty et al., 2008; Hunanyan et al., 2010;
Alilain et al., 2011; Bowes et al., 2012), they have not been so
effective in more traumatic injury models, such as compression
or contusion injury whereminimal or no improvements in func-
tion have been observed following localized intraparenchymal
injections (Iseda et al., 2008; Tom et al., 2009b; Harris et al., 2010;
Jakeman et al., 2011). The current study supports the hypothesis
that in clinically relevant traumatic models, where secondary
damage and inflammation is more severe, sustained delivery
leading to large-scale CSPGdigestion is necessary, and this can be
achieved by LV-ChABC.
Figure8. Genedelivery of ChABC leads to improved sensorimotor function and spinal conduction following spinal contusion.A, Impact data showing theactual force applied to individual animals
was within 10% of the intended force of 150 kdyne and mean values for each group were not significantly different (n 14 per group; p
 0.05; 1-way ANOVA), confirming that any group
differences were not due to differences in the impact force during surgery. B, Treatment with LV-ChABC leads to an early and sustained improvement in sensorimotor function, as shown by a
significant reduction in footslips on the horizontal ladder task at all postinjury time points compared with contusion only and contusion plus LV-GFP treatment; p 0.01, two-way repeated-
measures ANOVA, Bonferroni’s post hoc). C, Following treatmentwith LV-ChABC, there is a significant improvement in the percentage of sensory dorsal column axons that are capable of conducting
through the injury site at a chronic (10 weeks) postinjury time point ( p 0.01, 1-way ANOVA, Tukey’s post hoc). D, Example traces of recordings.
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Improved function with ChABC gene delivery
The functional consequences of large-scale CSPG digestion have
not previously been assessed. Here we saw a significant and sus-
tained recovery on the horizontal ladder test following LV-
ChABC treatment, which is likely due to early neuroprotective
effects since these animals never reached the same level of impair-
ment as the other groups on this task, despite an injury of the
same severity. This is in line with our histological observations of
neuroprotection and reduced apoptosis at 1 week postinjury and
long-term tissue preservation following LV-ChABC treatment.
The observed improvement in conduction of dorsal column ax-
ons through the injury site at a chronic postinjury time point is
also likely to be due primarily to the significant sparing of spinal
tissue following treatment with LV-ChABC, although we cannot
rule out the possibility that there may have been some regenera-
tion of dorsal column axons that could also account for improved
conduction. Alleviation of conduction block is also likely to be a
contributing factor, since CSPGs have previously been shown to
block conduction following spinal cord injury (Hunanyan et al.,
2010). A further potential contributing factor to improved ax-
onal conduction is enhanced remyelination, since ChABC has
previously been shown to increase the recruitment of oligoden-
drocyte precursor cells (Siebert et al., 2011) and M2 polarization
has recently been shown to play an essential role in CNS remyeli-
nation (Miron et al., 2013).
Proteoglycan andmacrophage modulation by ChABC
gene delivery
The local inflammatory response following spinal cord injury is
known to be neurotoxic and inhibitory to regeneration (Silver
and Miller, 2004). Previous work has shown that classically acti-
vated M1 macrophages are rapidly induced and maintained at
sites of traumatic spinal cord injury, followed by a smaller and
transientM2macrophage response (Kigerl et al., 2009;David and
Kroner, 2011). In vitro and in vivo evidence suggests that M1
macrophages are neurotoxic (Kigerl et al., 2009) while M2 mac-
rophages promote resolution of inflammation, angiogenesis, and
tissue remodelling and exhibit enhanced phagocytic properties
following injury (Mantovani et al., 2002). Polarizing macro-
phages toward an M2 phenotype may therefore limit secondary
inflammatory-mediated injury (Kigerl et al., 2009). In this study
we showed that LV-ChABC treatment induced expression of
CD206, a well characterized marker of M2macrophage polariza-
tion, inmacrophages in the lesion epicenter at 2weeks postinjury.
Moreover, our data indicate that the upregulation of CD206 is
mediated by a soluble factor(s) present in the injury penumbra,
since conditioned medium derived from ex vivo injured cord
explants was able to induce CD206 on resting THP-1 monocytic
cells and this was enhanced by ChABC activity. The upregulation
of CD206 in LV-ChABC-treated cords was preceded by an early
and transient increase in CD68, a lysosomal protein whose ex-
pression and post-translational modification is increased in ac-
tively phagocytic macrophages (Damoiseaux et al., 1994; da Silva
and Gordon, 1999). Early phagocytosis of apoptotic cells and
myelin debris could enhance repair and correlates well with the
tissue preservation and neuroprotection that we observed in LV-
ChABC-treated cords. In support of this hypothesis, Boven et al.
(2006) showed thatmyelin ingestion bymacrophages inmultiple
sclerosis lesions is associated with upregulation of CD206, M2
polarization, and increased immunoregulatory activity.
CD206-positive macrophages in LV-ChABC-treated tissue
were not always associated with IBA1 immunostaining, indicat-
ing that these cells were not exclusively derived from local acti-
vated microglia. Accordingly, we found CD206-positive cells
Figure9. Genedelivery of ChABC leads to increased serotonergic innervation following spinal contusion.A–D, Serotonergic (5-HT) fiber density is significantly enhanced in the ventral horn of the
lumbar spinal cord following treatmentwith LV-ChABC (C) comparedwith contusion only (A) and LV-GFP (B; quantified inD;n4per group;p0.05, 1-wayANOVA, Tukey’spost hoc).E–G, C-4-S
immunoreactivity is abundant in the lumbar cord of LV-ChABC-treated animals (F ), but absent in both LV-GFP and contusion-only animals (E; quantified in G; n 4 per group; p 0.001, 1-way
ANOVA, Tukey’s post hoc); boxes in A and E show regions where intensity measurements were quantified. Scale bar: (in C) A–C, 250m; (in F ) E, F, 500m.
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associated with blood vessels in the lesion epicenter, penumbra,
andmeninges, suggesting that theymay originate from the circu-
lation. Moreover, these cells could also promote angiogenesis, a
well known feature of alternative activation (Sica andMantovani,
2012). To this end, we found that CD206-positive cells in the
injury epicenter of LV-ChABC-treated cords were closely associ-
ated with VEGF, a central angiogenic mediator. Interestingly,
Shechter et al. (2013) recently demonstrated that infiltrating
monocyte-derived macrophages enhanced tissue recovery and
repair following spinal cord injury inmice and that these traffick-
ingmonocytes haveM2phenotypic characteristics. Similarly, Ev-
ans et al. (2014) showed that themajority of accumulating cells in
murine dorsal column crush lesions are circulation derived.
Altered glial scar formation was also observed following LV-
ChABC treatment, with more diffuse, elongated astrocytic pro-
cesses observed around the lesion penumbra, in contrast to the
thick border of astrogliosis apparent in control tissue, and typi-
cally observed around cavity edges following spinal contusion
(James et al., 2011). Interestingly, the potential of CSPGs to di-
rectly influence reactive astrogliosis and
support a heightened state of microglial
activation and chronic inflammation has
recently been demonstrated in the mi-
croenvironment of brain tumors (Silver et
al., 2013). Additionally, CSPG degradation
products released upon ChABC treatment
might play a role in influencing inflam-
matory or other cells, since free CS-GAGs
have previously been shown to repolar-
ize retinal ganglion cells and nerve fibers
within the retinal neuroepithelium
(Brittis and Silver, 1994) and free CS di-
saccharides can be neuroprotective in
inflammation-induced neuropatholo-
gies (Rolls et al., 2006).
Versican was rapidly induced in the le-
sion epicenter after spinal contusion, but
levels were significantly reduced in LV-
ChABC-treated cords 2 weeks postinjury.
Versican has been previously shown to ac-
cumulate in spinal injury lesions and is be-
lieved to be inhibitory to axon growth
(Jones et al., 2003).Recent evidence suggests
that versicanplays a role inmacrophage reg-
ulation since versican fragments have been
shown to activate macrophages via toll-like
receptor 2 (Kim et al., 2009), which is espe-
cially abundant in M1 macrophages (Man-
tovani et al., 2002) and involved in classical
activation (Monaco et al., 2009). Addition-
ally, versican has been used as a marker of
M1 polarization in human monocytes acti-
vated in vitro by IFN and LPS (Martinez et
al., 2006). Moreover, concomitant with the
decrease in versican, we observed an in-
crease in aggrecan following LV-ChABC
treatment. Aggrecan has previously been
implicated in neuroprotection, since
neurons associated with aggrecan-based
perineuronal nets are protected against
tau pathology in Alzheimer’s disease
(Morawski et al., 2010). Thus, the dif-
ferential expression of versican and ag-
grecan, known to be involved in M1 polarization and
neuroprotection, respectively, supports our findings for posi-
tive ECM remodeling and tissue repair following ChABC gene
delivery.
Enhanced serotonergic innervation following ChABC
gene delivery
While the findings of immune cell modulation following LV-
ChABC treatment were unpredicted, we observed expected
effects on descending fiber sprouting, since a well known conse-
quence of CSPG digestion is to enhance anatomical sprouting
andplasticity (for review, seeKwok et al., 2012; Bartus et al., 2012;
Burnside and Bradbury, 2014). Serotonergic projections to the
ventral horn are important for locomotor function (Saruhashi et
al., 1996) and our observations of enhanced serotonergic inner-
vation caudal to the injury are in agreement with previous studies
using ChABC (Barritt et al., 2006; Karimi-Abdolrezaee et al.,
2010) or other plasticity-enhancing therapeutics (Li et al., 2005;
McKillop et al., 2013). However, the neuroprotective effects of
Figure 10. Long-term CSPG digestion does not lead to an enhanced pain state in uninjured animals or following spinal contu-
sion.A,B, Assessments ofwithdrawal thresholds tomechanical (von Frey test;A) or thermal (Hargreaves test;B) stimulation of the
forepaw following injection of saline or LV-ChABC into the C5 spinal cord revealed no significant changes in pain sensitivity over a
12week time course. C,D, Injection of formalin to elicit a pain response in uninjured animals resulted in typical biphasic licking and
biting behaviors in the affected forepaw, with no significant differences observed between groups during the early or late phases
of the formalin-evoked response, indicating no enhanced sensitivity to pain following long-term treatment with LV-ChABC (n
7–8 per group; p
 0.05 2-way repeated-measures ANOVA for time course data and Student’s t test for early-phase and late-
phase data). E, F, Assessments of withdrawal thresholds to mechanical (von Frey test; E) or thermal (Hargreaves test; F ) stimula-
tion of the hindpaw following T10 spinal contusion and injection of LV-GFP or LV-ChABC at the injury site revealed no significant
changes in pain sensitivity over a 10 week time course (n 7–8 per group; p
 0.05 2-way repeated-measures ANOVA).
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LV-ChABC may also have contributed to the serotonergic fiber
increase, since tissue preservation at the epicenter will likely have
spared some descending serotonergic projections. These findings
suggest that widespread CSPG digestion can promote changes in
serotonergic fiber density, whether by axonal sparing, fiber
sprouting, or both, at sites distal to the injury. Widespread CSPG
digestion may also be important for the immunomodulatory ef-
fects of LV-ChABC, since activatedmacrophages typically spread
over several spinal segments following contusion injury (David
and Kroner, 2011), likely requiring treatment of a large area to
elicit significant macrophage modulation.
The efficacy of LV-ChABC, alongwith alternative strategies to
modify scar-associated molecules, such as microtubule stabiliza-
tion (Hellal et al., 2011) and direct targeting of specific CSPG
epitopes (Brown et al., 2012), highlights the importance of tar-
geting the ECM to promote repair following spinal cord injury.
There are a number of possible issues to consider in terms of
LV-ChABCdevelopment toward a clinical therapeutic, including
the risk of insertional mutagenesis posed by integrating LVs, as
has been reported for other retroviral vectors (Hacein-Bey-Abina
et al., 2003). However, no such effect has been so far observed in
the primateCNS (Jarraya et al., 2009) or in on-going clinical trials
(Palfi et al., 2014). Additionally, although previous studies have
found no enhanced pain sensitivity following ChABC treatment
(Barritt et al., 2006;Galtrey et al., 2007; Karimi-Abdolrezaee et al.,
2010) and in the present study LV-ChABC did not lead to en-
hanced sensitivity to noxious or non-noxious stimuli up to 12
weeks post-treatment, we do not know whether longer-term
large-scale CSPG digestion could eventually have detrimental ef-
fects. Therefore, it would be optimal to regulate ChABC gene
expression, for example by using an LV with an inducible pro-
moter (Blesch et al., 2005; Sooksawate et al., 2013).
Thus, using a gene delivery vector-based approach that en-
ables resident CNS cells to stably secrete ChABC in vivo, we dem-
onstrate potent effects on reducing secondary injury pathology
and restoring function in a clinically relevant model of traumatic
spinal contusion. Furthermore, these improvements are associ-
atedwith remodelling ofmatrixmolecules andmodulation of the
immune response. These findings have widespread implications
for the treatment of spinal injuries and other pathological disease
states.
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